Tony Coles sets sail on new neuro pursuit at Cerevel, steering Pfizer spinout as CEO
For nine months, Tony Coles has been watching closely as Adam Koppel and Bain’s life sciences team built Cerevel from the ground up, offering insights into its neuroscience pursuit as executive chairman while staying at the helm of his own biotech. But now that he has passed the reins at Yumanity to Richard Peters, Coles is completing the flip — and the top team puzzle — by taking the chief executive role at Cerevel.
“I’m excited because I get double the opportunity to play a role in two important companies,” Coles noted in an interview with Endpoints News.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 66,100+ biopharma pros reading Endpoints daily — and it's free.